[Annonce événementielle selon l’art. 53 RC] Roche annonce une forte croissance des ventes dans les activités de base de ses deux divisions au T1 ; le recul des ventes du Groupe est dû à la baisse attendue de la demande de tests COVID-19
26 avr. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Bâle, le 26 avril 2023 Comme attendu, la baisse significative de la demande de tests COVID-19 entraîne une diminution des ventes du Groupe (-3 %1 à taux de change constants [TCC] et -7 % en francs...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
26 avr. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this...
New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
25 avr. 2023 15h00 HE
|
F. Hoffmann-La Roche Ltd
Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular...
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
19 avr. 2023 15h30 HE
|
F. Hoffmann-La Roche Ltd
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin...
Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
16 avr. 2023 11h00 HE
|
F. Hoffmann-La Roche Ltd
In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1Up to 80% of people with this...
Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023
13 avr. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Vabysmo data suggest rapid and robust drying of retinal fluid in patients with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema Real-world studies of Vabysmo...
Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
22 mars 2023 02h00 HE
|
F. Hoffmann-La Roche Ltd
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma PanelThe Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing...
New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
20 mars 2023 02h00 HE
|
F. Hoffmann-La Roche Ltd
Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to...
Assemblée générale 2023 de Roche
14 mars 2023 08h45 HE
|
F. Hoffmann-La Roche Ltd
Adoption de toutes les propositions du Conseil d’administrationSeverin Schwan a été élu président du Conseil d’administration et tous les autres membres du Conseil d’administration candidats ont été...
Roche Annual General Meeting 2023
14 mars 2023 08h45 HE
|
F. Hoffmann-La Roche Ltd
All proposals of the Board of Directors approvedSeverin Schwan elected as new Chairman of the Board of Directors; all other members of the Board of Directors standing for election were electedThomas...